Baxter International Inc. (NYSE:BAX) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in ...
ADVATE (antihemophilic factor [recombinant] plasma/albumin-free method) 4000IU for IV use by Baxter Baxter announced that the FDA has approved a new 4000 IU dosage strength of Advate (Antihemophilic ...
Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis ...
Baxter International Inc., a global, diversified healthcare company, has received approval from China State Food and Drug Administration (SFDA) for Advate [Recombinant Human Coagulation Factor VIII ...
The hemophilia A treatment Advate is the cornerstone to the future of Baxalta ($BXLT), the company that was created when Baxter International ($BAX) spun off its drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback